| Type | Title | Date Released | |
|---|---|---|---|
8-A12B | Form 8-A12B New | ||
6-K | Polyrizon Ltd. Adopts Limited Duration Shareholder Rights Plan New | ||
6-K | Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker | ||
S-8 | Form S-8 | ||
6-K | Polyrizon Files U.S. Divisional Patent Application for Intranasal Drug-Delivery Platform | ||
EFFECT | Form EFFECT | ||
F-1/A | SHARE RESALE REGISTRATION | Shares: 404,166 EFFECTIVE, DATED 2026-10-01 | ||
6-K | Polyrizon Ltd. Reports Second Quarter 2026 Financial Results and Balance Sheet | ||
F-1 | SHARE RESALE REGISTRATION EFFECTIVE, DATED 2026-10-01 | ||
D | Form D | ||
6-K | Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement | ||
6-K | Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement |
